These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513 [TBL] [Abstract][Full Text] [Related]
7. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Hsu YC; Sung SF; Ong CT; Wu CS; Su YH Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569 [TBL] [Abstract][Full Text] [Related]
8. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Labiche LA; Al-Senani F; Wojner AW; Grotta JC; Malkoff M; Alexandrov AV Stroke; 2003 Mar; 34(3):695-8. PubMed ID: 12624293 [TBL] [Abstract][Full Text] [Related]
9. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome? Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920 [TBL] [Abstract][Full Text] [Related]
11. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774 [TBL] [Abstract][Full Text] [Related]
12. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462 [TBL] [Abstract][Full Text] [Related]
13. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time. Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612 [TBL] [Abstract][Full Text] [Related]
14. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y; Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020 [TBL] [Abstract][Full Text] [Related]